Kymera Therapeutics, Inc.
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company developing oral medicines, principally using targeted protein degradation, to eliminate disease-causing proteins. Its discovery and development work focuses mainly on immunology, including programs targeting STAT6 and IRF5, as well as an… From the company’s description.
In fiscal 2025, Kymera Therapeutics, Inc. reported revenue of $39.21M, down 16.7% from fiscal 2024, and a net loss of $311.35M. Its operating margin was −891.1%, and operations used $232.89M in cash. Over the twelve months to Jun 30, 2026, revenue was $105.00M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kymera Therapeutics, Inc. does
In the company’s own words
Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company developing oral medicines, principally using targeted protein degradation, to eliminate disease-causing proteins. Its discovery and development work focuses mainly on immunology, including programs targeting STAT6 and IRF5, as well as an IRAK4 degrader being developed with Sanofi. Its STAT6 candidate KT-621 is in Phase 2b trials for atopic dermatitis and asthma, while its IRF5 candidate KT-579 has entered Phase 1 testing. The company also collaborates with Gilead on molecular glue degraders targeting CDK2, a program with potential applications in cancer. Kymera uses its discovery capabilities to pursue targets that have been difficult to address with conventional medicines, and aims to develop small-molecule therapies for patients with serious diseases. It relies on third-party manufacturers to produce drug candidates for preclinical studies and clinical trials. The company’s disclosed activities are organized around research and development programs and collaborations; the filing identifies no reportable operating segments.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- WATERTOWN, MA
- Fiscal year end
- December
- CIK
- 1815442
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kymera Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kymera Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kymera Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kymera Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kymera Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”